Meaverin (Mepivacaine Hydrochloride)

Mepivacaine blocks voltage‑gated sodium channels on nerve membranes, stabilising them in an inactive state. This prevents the generation and propagation of action potentials, thereby interrupting pain signal transmission and producing a reversible loss of sensation in the targeted area.

The specific dose of Meaverin is determined by the prescribing clinician based on the procedure, patient characteristics, and regulatory guidelines. Healthcare professionals calculate the appropriate volume and concentration to achieve effective anesthesia while staying within safe limits.

Safety of mepivacaine in pregnancy or lactation has not been definitively established. It should be used only when the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Meaverin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mepivacaine offers a rapid onset and intermediate duration of action, similar to lidocaine but with slightly less vasodilatory effect, which can reduce the need for a vasoconstrictor. Compared with bupivacaine, it has a shorter duration and a lower risk of cardiotoxicity, making it suitable for shorter procedures.

Meaverin should be stored at temperatures below 25 °C, in its original sealed container, protected from light and moisture. Avoid freezing the solution. Before use, inspect the vial for particulate matter or discoloration and handle with aseptic technique.

Meaverin is supplied as a sterile solution and is administered by a qualified healthcare professional via epidural, intradermal or subcutaneous injection, depending on the clinical indication. The injection technique follows standard aseptic procedures and dosage is calculated by the prescriber.

Serious risks include allergic reactions such as anaphylaxis, cardiac arrhythmias, central nervous system toxicity leading to seizures, and rare cases of methemoglobinemia. Prompt recognition and management of these events are essential, and patients should be monitored during and after administration.

Meaverin is contraindicated in patients with a known hypersensitivity to mepivacaine or other amide‑type local anesthetics. It should also be avoided in individuals with severe cardiac conduction disorders, uncontrolled epilepsy, or those who have experienced severe reactions to similar agents.